many good hints re phase 3, page-19

http://www.nasdaq.com/article/cancer-biotech-audeo-oncology-withdraws-49-million-ipo-cm326649

Cancer biotech Audeo Oncology withdraws $49 million IPO
By Renaissance Capital, February 14, 2014, 07:55:08 AM EDT
Vote up

Audeo Oncology, which is developing a combination therapy in Phase 3 trial for metastatic colorectal cancer, withdrew its plans for an initial public offering on Friday. The company had launched its deal in November 2012 but ultimately postponed its offering in December 2012. The San Francisco, CA-based company was founded in 2006. Leerink Partners and Oppenheimer & Co. were set to be the joint bookrunners on the deal.